APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress

被引:27
|
作者
Wakashin, Hidefumi [1 ]
Heymann, Jurgen [1 ]
Roshanravan, Hila [1 ]
Daneshpajouhnejad, Parnaz [2 ]
Rosenberg, Avi [2 ]
Shin, Myung Kyun [3 ]
Hoek, Maarten [4 ]
Kopp, Jeffrey B. [1 ]
机构
[1] NIDDK, Kidney Dis Sect, NIH, KDB, 10 Ctr Dr,3N116, Bethesda, MD 20892 USA
[2] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[3] Merck & Co Inc, Merck Res Labs, Kenilworth, NJ USA
[4] Maze Therapeut, Redwood City, CA USA
关键词
APOL1; Protein isoform; Interleukin-1; beta; NLRP12; Podocytes; Kidney; Chronic kidney disease; Inflammatory stress; APOLIPOPROTEIN-L GENE; KIDNEY-DISEASE; CXCR3; LIGANDS; EXPRESSION; PROTEIN; IDENTIFICATION; LOCALIZATION; NEPHROPATHY; INHIBITOR; CLUSTER;
D O I
10.1186/s12882-020-01995-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Apolipoprotein L1, APOL1, is a trypanosome lytic factor present in human and certain other primates.APOL1gene variants, present in individuals of recent sub-Saharan African descent, increase risk for glomerular disease and associate with the disease progression, but the molecular mechanisms have not been defined. Objectives We focus on the mechanism how APOL1 variant proteins enhance podocyte injury in the stressed kidney. Methods First, we investigated the expression of APOL1 protein isoform and the localization of APOL1 protein in the kidney. Next, we examined the role of APOL1 in the podocyte stress and the inflammatory signaling in the kidney after hemi-nephrectomy. Results We identified a novel RNA variant that lacks a secretory pathway signal sequence and we found that the predicted APOL1-B3 protein isoform was expressed in human podocytes in vivo and by BAC-APOL1 transgenic mice. APOL1-B3-G2 transgenic mice, carrying a renal risk variant, manifested podocyte injury and increased pro-IL-1 beta mRNA in isolated glomeruli and increased IL-1 beta production in the remnant kidney after uninephrectomy. APOL1-B3 interacted with NLRP12, a key regulator of Toll-like receptor signaling. Conclusions These results suggest a possible mechanism for podocyte injury by which one of the APOL1 protein isoforms, APOL1-B3 and its renal risk variants, enhances inflammatory signaling.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] APOL1 Kidney Disease Risk Variants: An Evolving Landscape
    Dummer, Patrick D.
    Limou, Sophie
    Rosenberg, Avi Z.
    Heymann, Jurgen
    Nelson, George
    Winkler, Cheryl A.
    Kopp, Jeffrey B.
    SEMINARS IN NEPHROLOGY, 2015, 35 (03) : 222 - 236
  • [22] Balancing the genetic risk of APOL1 kidney disease variants
    Kabore, Nongodo Firmin
    Limou, Sophie
    NEPHROLOGIE & THERAPEUTIQUE, 2019, 15 : S79 - S84
  • [23] APOL1 Risk Variants and Acute Kidney Injury in Black Americans with COVID-19
    Larsen, Christopher P.
    Wickman, Terrance J.
    Braga, Juarez R.
    Matute-Trochez, Luis A.
    Hasty, Anna E.
    Buckner, Lyndsey R.
    Arthur, John M.
    Haun, Randy S.
    Velez, Juan Carlos Q.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (12): : 1790 - 1796
  • [24] Nonpodocyte Roles of APOL1 Variants: An Evolving Paradigm
    Pell, John
    Nagata, Soichiro
    Menon, Madhav C.
    KIDNEY360, 2023, 4 (09): : 1325 - 1331
  • [25] APOL1 Gene Variants and Risk for Cardiovascular Disease
    Duran, Carlos Eduardo
    Estacio, Mayra
    Espinosa, Daniela
    Manzi, Eliana
    Posada, Juan G.
    Mesa, Liliana
    Schweineberg, Johanna
    KIDNEY & BLOOD PRESSURE RESEARCH, 2023, 48 (01) : 785 - 790
  • [26] APOL1 Genetic Variants Are Associated With Increased Risk of Coronary Atherosclerotic Plaque Rupture in the Black Population
    Cornelissen, Anne
    Fuller, Daniela T.
    Fernandez, Raquel
    Zhao, Xiaoqing
    Kutys, Robert
    Binns-Roemer, Elizabeth
    Delsante, Marco
    Sakamoto, Atsushi
    Paek, Ka Hyun
    Sato, Yu
    Kawakami, Rika
    Mori, Masayuki
    Kawai, Kenji
    Yoshida, Teruhiko
    Latt, Khun Zaw
    Miller, Clint L.
    de Vries, Paul S.
    Kolodgie, Frank D.
    Virmani, Renu
    Shin, Myung Kyun
    Hoek, Maarten
    Heymann, Jurgen
    Kopp, Jeffrey B.
    Rosenberg, Avi Z.
    Davis, Harry R.
    Guo, Liang
    Finn, Aloke V.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2021, 41 (07) : 2201 - 2214
  • [27] APOL1 Nephropathy Risk Variants Through the Life Course: A Review
    Itoku, Ai
    Isaac, Jaya
    Wilson, Scott
    Reidy, Kimberly
    Kaskel, Frederick
    Wilson, S. M.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 84 (01) : 102 - 110
  • [28] The biology of APOL1 with insights into the association between APOL1 variants and chronic kidney disease
    Sethu M. Madhavan
    John F. O’Toole
    Clinical and Experimental Nephrology, 2014, 18 : 238 - 242
  • [29] One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants
    Kopp, Jeffrey B.
    Rosenberg, Avi Z.
    ADVANCES IN ANATOMIC PATHOLOGY, 2019, 26 (03) : 215 - 219
  • [30] Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte
    Heymann, Jurgen
    Winkler, Cheryl A.
    Hoek, Maarten
    Susztak, Katalin
    Kopp, Jeffrey B.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 65 - 70